On the stock market since 2025, it operates in the world of health and science. It has 10 employees. Now — the numbers.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 60% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 3/10.
On our five-subject report card, RGNT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RGNT is a high-risk stock — not yet profitable, and its future rides on its product catching on.